Howe Jolanda

SVP Global Controller Howe sold 10,000 shares (80.5% of holdings) at $58.00 on 2025-08-07, reducing stake to 2.4K shares.

Jolanda Howe, SVP Global Controller, executed a substantial sale of 10,000 shares for $580,000, representing an 80.5% reduction in her MIRM holdings. The sale occurred at $58.00, slightly below the current price of $59.97 and just shy of the 52-week high of $59.97. Howe's prior four trades at MIRM (all sales on 2025-03-17) were poorly timed: all four showed negative 30-day returns averaging -12.8% but positive 90-day returns (well-timed if the stock fell after, but it rose instead), with 0 of 4 trades well-timed at the 90-day mark. The company is growing rapidly (revenue +80.8% annually) but remains unprofitable with $-5.9M net income on $127.8M in latest quarterly revenue. This sale does not signal a clear market-timing insight; rather, it reduces Howe's direct exposure to a high-growth but loss-making pharmaceutical firm to a minimal stake of 2.4K shares.

SVP Global Controller Jolanda Howe sells 57,606 shares (92.2% of holdings) for $2,554,762.73 at Mirum Pharmaceuticals

Jolanda Howe, SVP and Global Controller at Mirum Pharmaceuticals, executed 4 separate sales totaling 57,606 shares for $2,554,762.73 on 2025-03-17, reducing her holdings from 62,447 shares to 4,841 shares—a 92.2% reduction. This represents a nearly complete liquidation of her position at a blended average price of $44.35, executed as the stock trades -16.6% from its 52-week high of $53.16 and -11.4% over the prior 30 days. The scale of the divestiture is material: an insider with significant financial responsibility at a company generating $90.4M in quarterly revenue with -$14.2M net income is substantially exiting her equity stake. The timing occurs amid deteriorating near-term momentum, though the company has posted +80.8% annual revenue growth.